In short
This article discusses clinical trials investigating the use of Inupadenant Hydrochloride, a novel drug, in treating advanced solid tumors and non-small cell lung cancer (NSCLC). The trials aim to evaluate the safety, efficacy, and optimal dosing of Inupadenant Hydrochloride when used alone or in combination with other cancer treatments.
At a glance
- Drug Name
- Inupadenant Hydrochloride
- Cancer Types Studied
- Advanced solid tumors, metastatic non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC)
- Trial Phases
- Phase I/II and Phase II
- Administration
- Oral capsules
- Combination Therapies
- Carboplatin, pemetrexed, dostarlimab, pembrolizumab
- Primary Objectives
- Safety, tolerability, efficacy, optimal dosing
- Key Endpoints
- Progression-free survival (PFS), overall response rate (ORR), adverse events
- Eligibility
- Adults with advanced solid tumors or specific lung cancers, meeting health criteria
What is Inupadenant Hydrochloride?
Inupadenant Hydrochloride, also known as EOS100850, is an investigational drug being developed for the treatment of advanced solid tumors. It is a chemical compound that belongs to a class of drugs called immunotherapies, which work by enhancing the body's immune system to fight cancer.
How It Works
While the exact mechanism of action is not fully described in the provided clinical trial information, inupadenant hydrochloride is likely designed to target specific pathways in the immune system. It may work by blocking certain proteins or receptors that cancer cells use to evade the immune system, thereby allowing the body's natural defenses to recognize and attack the tumor cells more effectively.
Conditions Treated
Inupadenant hydrochloride is being studied for the treatment of various advanced solid tumors. Specifically, it is being investigated for:
- Non-small cell lung cancer (NSCLC): Particularly in patients with metastatic or locally advanced, unresectable Stage III nonsquamous NSCLC that has relapsed or progressed.
- Head and neck squamous cell carcinoma (HNSCC): In patients with first-line metastatic HNSCC.
- Cutaneous melanoma: Specifically in patients with anti-PD-(L)1 resistant metastatic cutaneous melanoma.
Clinical Trials
Inupadenant hydrochloride is currently being evaluated in several clinical trials:
1. A Phase I/II study (2024-512227-36-00) is investigating the drug in combination with other therapies for advanced solid tumors. This study aims to:
- Determine the safety and tolerability of inupadenant in combination with other treatments
- Identify the recommended Phase 2 dose (RP2D)
- Assess the anti-tumor activity in various cancer types
2. A Phase II study (2024-515393-27-00) is evaluating inupadenant in combination with carboplatin and pemetrexed for nonsquamous non-small cell lung cancer (NSCLC) patients who have progressed on immunotherapy. This study aims to:
- Evaluate the efficacy and safety of the combination treatment
- Assess progression-free survival (PFS) as the primary endpoint
- Measure overall response rate (ORR), duration of response (DoR), and overall survival (OS) as secondary endpoints
Potential Benefits
While the full results of these clinical trials are not yet available, inupadenant hydrochloride shows promise in treating advanced solid tumors, particularly in patients who have progressed on previous treatments. Potential benefits being investigated include:
- Improved anti-tumor activity when combined with other therapies
- Potential efficacy in patients who have become resistant to other immunotherapies
- Possible extension of progression-free survival and overall survival
Side Effects and Safety
As with all investigational drugs, the full safety profile of inupadenant hydrochloride is still being determined through clinical trials. The studies are carefully monitoring for adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs). Patients considering participation in clinical trials should discuss potential risks and side effects with their healthcare provider.
Administration
Inupadenant hydrochloride is being studied in capsule form for oral administration. The optimal dosing schedule and duration of treatment are still being determined through the ongoing clinical trials.
Future Research
As inupadenant hydrochloride continues to be studied, future research may focus on:
- Identifying biomarkers to predict which patients are most likely to benefit from the treatment
- Exploring additional combination therapies to enhance efficacy
- Investigating its potential in other types of solid tumors
- Long-term follow-up to assess durability of response and overall survival benefits
Patients interested in learning more about inupadenant hydrochloride or participating in clinical trials should consult with their oncologist to determine if they may be eligible for ongoing studies.